GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: BoE expects strong UK growth in 2nd quarter

Thu, 06th May 2021 12:09

(Alliance News) - Stock prices in London were marginally higher at midday on Thursday in the wake of the Bank of England's latest interest rate decision, while US drugmakers were in focus after the Biden administration backed a plan to waive Covid-19 vaccine patents.

The central bank left the key UK interest rate unchanged at 0.1% and its quantitative easing programme untouched, with the total target stock of asset purchases at GBP895 billion.

The Bank of England said the outlook for the UK economy remains uncertain due to the virus pandemic. It predicted that gross domestic product will increase sharply in the second quarter but for growth slow thereafter as the boost from reopening wanes.

Following the BoE announcement, the pound was quoted at USD1.3902 at midday Thursday, down from USD1.3910 at the London equities close Wednesday.

Just prior to the announcement, FTSE 100 index was up 15.22 points, or 0.2%, at 7,054.52. The mid-cap FTSE 250 index was up 128.35 points, or 0.6%, at 22,514.25. The AIM All-Share index was down 0.6% at 1,254.10.

The Cboe UK 100 index was up 0.1% at 702.20. The Cboe 250 was up 0.7% at 20,205.81, and the Cboe Small Companies up 0.2% at 14,739.26.

In mainland Europe, the CAC 40 in Paris was down 0.1%, while the DAX 30 in Frankfurt was down 0.2%.

On the economic front, UK services sector activity growth hit a seven-and-a-half year high in April as lockdown restrictions eased, according to IHS Markit.

The IHS Markit/CIPS UK services purchasing managers' index was revised higher to 61.0 points in April from a preliminary estimate of 60.1, having registered 56.3 in March.

The latest reading signalled the fastest pace of expansion in the sector since October 2013.

In the FTSE 100, Next was the best performer, up 3.5%, after the high street and online retailer boosted its full-year profit guidance for a second time this year following a strong first quarter.

Next said full price sales were down 1.5% in the 13 weeks to May 1 on two years ago, before the Covid-19 pandemic, which the company said was a more "meaningful" comparison.

The FTSE 100 clothing and homewares retailer said it had assumed full-price sales during period would be down 10%, but beat this forecast by GBP75 million. As such, Next raised its central guidance for full-year pretax profit by GBP20 million to GBP720 million.

In April, the Leicester, England-based firm had raised its central profit guidance by GBP30 million to GBP700 million and "optimistically" ruled out further store closures as the UK's vaccine rollout continued.

Looking ahead, Next said it expects the recent post-lockdown sales surge to be short lived - based on the experience of last year - with sales to settle back toward guidance levels within the next few weeks.

Barratt Developments was up 2.0%. The housebuilder said it has performed well since the start of the calendar year reflecting underlying market strength and strong customer demand for "high-quality sustainable new homes".

For the period from January 1 to this past Sunday, total forward sales were GBP3.7 billion, up 31% from GBP2.83 billion at the same time in 2020, and it delivered 4,481 home completions, up 28% from 3,504.

The increase in completions in the period reflected the delivery of customers' homes in line with the UK government's original Help to Buy scheme and the stamp duty holiday deadlines, Barratt said.

Mexican miner Fresnillo was up 1.3%, tracking spot gold prices higher. The precious metal was quoted at USD1,793.58 an ounce Thursday midday, up from USD1,781.79 late Wednesday.

National Grid was up 1.2% after Berenberg raised the UK power lines operator to Buy from Hold.

Melrose Industries was up 1.0%. The industrial turnaround specialist said that, in the four months to April 30, trading was modestly ahead of expectations.

Melrose said the momentum seen in the second half of 2020 has continued into 2021, with sales in the period being 8% higher than in the same period in 2020. Excluding Nortek Air Management, group sales grew by 4%. Last month, Melrose agreed to sell Nortek Chicago-based Madison Industries for GBP2.62 billion.

Further, Melrose said operating margins achieved in the first quarter of the year continued to improve faster than expected, and cash generation has been encouraging, with Melrose "being cash neutral in the first quarter, in what is traditionally a cash outflow period".

Looking ahead, Melrose said it expects improvements in trading to continue, but noted the growth rate will be hindered by supply issues for semi-conductors in the global automotive supply chain.

At the other end of the large-caps, Mondi was the worst performer, down 4.1%. The packaging firm said it delivered a "robust performance" in the first quarter despite an expected decline in earnings.

Mondi reported underlying earnings before interest, tax, depreciation and amortisation of EUR353 million, down 8.3% from EUR385 million a year ago. This was in line with the company's expectations, however. Ebitda was up 14% from EUR309 million in the fourth quarter of last year.

Admiral Group, Polymetal International and Croda International were among the worst performers, down 3.5%, 3.0% and 2.9% respectively. The stocks went ex-dividend meaning new buyers no longer qualify for the latest payout.

The euro was priced at USD1.2049, up from USD1.2000. Against the yen, the dollar was trading at JPY109.13, down from JPY109.26.

Polling stations were open for voters to cast their ballots in a set of elections which could shake up British politics and have profound implications for the future of the UK.

On what has been dubbed 'Super Thursday', polling stations opened across Great Britain in the largest test of political opinion outside a general election, with the future of the Labour Party and the state of the Union among the issues at play.

Scottish National Party leader Nicola Sturgeon's push for a second independence referendum means the stakes are high in the Holyrood contest.

In England, as well as local council and mayoral contests, the Hartlepool parliamentary by-election will indicate what progress - if any - Labour has made in regaining votes in its former northern heartlands.

"For GBP, the Scottish parliamentary elections are certainly the one that investors will be watching. If the Scottish National Party manage to achieve a majority, the chances of a Scottish independence referendum is high. This result could negatively impact the British currency, as without Scotland, the British economy weakens," said analysts at OFX.

Brent oil was trading at USD68.70 a barrel at midday, down sharply from USD69.89 late Wednesday.

US stock market futures were pointed higher with the latest jobless claims numbers in focus ahead of the nonfarm payrolls report due on Friday.

The Dow Jones Industrial Average was called up 0.1%, the S&P 500 index up 0.1%, and the Nasdaq Composite up 0.3%.

US President Joe Biden's administration on Wednesday announced support for a global waiver on patent protections for Covid-19 vaccines, offering hope to poor nations that have struggled to access the life-saving doses.

US Trade Representative Katherine Tai said that while intellectual property rights for businesses are important, Washington "supports the waiver of those protections for Covid-19 vaccines" in order to end the pandemic.

Tedros Adhanom Ghebreyesus, head of the World Health Organization, called the US decision "historic" and marked "a monumental moment in the fight against Covid-19."

Patents give drugmakers a short-term monopoly on production to cover the high costs of research and development. Biotech firms have argued that these protections provided incentives to produce Covid-19 vaccines in a short period.

Tai in recent weeks has met with executives from all the major US vaccine producers - Pfizer, Moderna and Johnson & Johnson - to discuss the issue.

Pfizer, Moderna, Novavax and J&J shares were down 3.1%, 2.2%, 5.6% and 0.6% respectively in pre-market trade in New York. In London, AstraZeneca was up 0.7% in London, but BioNTech - partner of Pfizer on Covid-19 vaccines - was down 16% in Frankfurt.

The economic events calendar on Thursday has US jobless claims at 1330 BST.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.